Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.francebleu.fr/sports/football/ligue-1-au-terme-d-un-match-sans-saveur-le-fc-metz-et-nantes-font-match-n
Are you over 18 and want to see adult content?
A complete backup of www.bbc.com/news/uk-england-london-51514716
Are you over 18 and want to see adult content?
A complete backup of applealmond.com/posts/67268
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of in.nba.com/news/golden-state-warriors-los-angeles-lakers-stephen-curry-klay-thompson-lebron-james-andrew-wi
Are you over 18 and want to see adult content?
A complete backup of www.cmmedia.com.tw/home/articles/19799
Are you over 18 and want to see adult content?
A complete backup of elcomercio.pe/deporte-total/futbol-mundial/atletico-nacional-vs-boyaca-chico-dia-hora-y-canal-del-duelo-por
Are you over 18 and want to see adult content?
Text
ELENA GARRALDA
PubMed PMID: 30327308. Blanca Homet Moreno, Elena Garralda, Ricardo Hitt.Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas,Clinical & translational Oncology, Educational Series 2010: 12; 468-472. DOI 10.1007/s12094-010-0539-z. J. Sepulveda and E. Garralda. EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCHEarly Clinical Drug Development Group. We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rational combinations of targeted therapies,biomarker-driven
VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia.CÉSAR SERRANO
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15;20 (22):5745-5755. George S, Barysauskas C, Serrano C, Oduyebo T,Rauh-Hain JA,
ANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcriptionJOAQUIN MATEO
Principal Investigator, Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO). Medical Oncologist & Attending Physician, Medical Oncology Department, Vall d’Hebron University Hospital (HUVH). Chair of the European Society for Medical Oncology´s (ESMO) Translational Research and Precision MedicineWorking
VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY iniciar sesión Copyright © VHIO 2021ONCOTRIALSTRACK
OncoTrialsTrack. Information displayed in OncoTrialsTrack is constantly updated but specific clinical trial recruitment plans may change on a daily basis. Therefore, clinical trial availability must be confirmed with principal investigators of the site. VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYABOUT VHIOPROGRAMS & GROUPSPRINCIPAL INVESTIGATORSCLINICAL TRIALSPROJECTS & INSTL PROGRAMS VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY Welcome to VHIO´s Intranet. Your very own personal dashboard provides you with confidential files including your salary details and your vacation records. You can also upload and organize your own documents, create groups with whom you wish to connect, browse up-to-the-minute VHIO news, and access a variety of organizational knowledge andELENA GARRALDA
PubMed PMID: 30327308. Blanca Homet Moreno, Elena Garralda, Ricardo Hitt.Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas,Clinical & translational Oncology, Educational Series 2010: 12; 468-472. DOI 10.1007/s12094-010-0539-z. J. Sepulveda and E. Garralda. EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCHEarly Clinical Drug Development Group. We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rational combinations of targeted therapies,biomarker-driven
VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia.CÉSAR SERRANO
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15;20 (22):5745-5755. George S, Barysauskas C, Serrano C, Oduyebo T,Rauh-Hain JA,
ANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcriptionJOAQUIN MATEO
Principal Investigator, Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO). Medical Oncologist & Attending Physician, Medical Oncology Department, Vall d’Hebron University Hospital (HUVH). Chair of the European Society for Medical Oncology´s (ESMO) Translational Research and Precision MedicineWorking
VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY iniciar sesión Copyright © VHIO 2021ONCOTRIALSTRACK
OncoTrialsTrack. Information displayed in OncoTrialsTrack is constantly updated but specific clinical trial recruitment plans may change on a daily basis. Therefore, clinical trial availability must be confirmed with principal investigators of the site. NEWLY APPOINTED ESMO FACULTY: VHIO INVESTIGATORS JOIN In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core priorities and objectives set out in its Vision 2020, ESMO has finalized its 2021 composition of expert committees and working groups, including newly appointed faculty members across various tumor types.. ESMO’s serving officers, including those who have just VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia. SPEARHEADING NEXT GENERATION CLINICAL TRIALS: CANCER CORE Incorporating experts from the seven European comprehensive cancer centers belonging to the Cancer Core Europe (CCE) Consortium, along with an additional four non-CCE partners*, the EU-funded, multi-site project CCE Building Data Rich Clinical Trials (CCE-DART), has now launched.; Coordinated by VHIO’s Elena Garralda, CCE-DART seeks to become a groundbreaking example in driving a novel ANA OAKNIN – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY ANA OAKNIN Current positions Principal Investigator, VHIO´s Gynecological Malignancies Group. Head of Gynecologic Tumors Unit, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Full-time Senior Medical Oncologist & Attending Physician, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Academic Qualifications Degree in Medicine and TREBALLA AMB NOSALTRES Oportunitats laborals Es busquen candidats per a diversos càrrecs en la Fundació Vall d'Hebron Institut d'Oncologia. Els candidats seleccionats duran a terme una recerca independent sobre la gènesi, l'evolució, el pronòstic, la prevenció i el tractament del càncer en sinergia amb els esforços continuats. Ofertes de treball:VIOLETA SERRA
Violeta Serra received La Marató funding to investigate mechanisms of resistance to therapy with PARP inhibitors (PARPi). By liquid biopsy, Violeta’s team will aim to establish whether the RAD51 biomarker, that can predict sensitivity to PARPi, can more effectively identify VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY iniciar sesión Copyright © VHIO 2021JOAN SEOANE
JOAN SEOANE jseoane@vhio.net Current positions May 2019- present: Director, co-Preclinical and Translational Research Program, VHIO, Barcelona, Spain. Director of Translational Research at VHIO Head of the Gene Expression and Cancer Laboratory ICREA Research Professor,2004 Member of the
PAOLO G. NUCIFORO
Academic Qualifications. 1997 Degree in Medicine and Surgery from the University of Catania (Italy) 2002 Board certification in Pathology from the University of Milan (Italy) 2003 2005 Research fellow at Firc Institute of Molecular Oncology, Milan. 2005-2007 Molecular Pathology Unit Coordinator at Firc Institute of Molecular Oncology, Milan.OFERTES DE FEINA
CELLEX CENTER C/ Natzaret, 115-117 08035 – BARCELONA – Spain Tel: +34 93 254 34 50 email: info@vhio.net VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYABOUT VHIOPROGRAMS & GROUPSPRINCIPAL INVESTIGATORSCLINICAL TRIALSPROJECTS & INSTL PROGRAMS VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY Welcome to VHIO´s Intranet. Your very own personal dashboard provides you with confidential files including your salary details and your vacation records. You can also upload and organize your own documents, create groups with whom you wish to connect, browse up-to-the-minute VHIO news, and access a variety of organizational knowledge and EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCHEarly Clinical Drug Development Group. We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rational combinations of targeted therapies,biomarker-driven
ELENA GARRALDA
PubMed PMID: 30327308. Blanca Homet Moreno, Elena Garralda, Ricardo Hitt.Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas,Clinical & translational Oncology, Educational Series 2010: 12; 468-472. DOI 10.1007/s12094-010-0539-z. J. Sepulveda and E. Garralda.JOAN CARLES
JOAN CARLES jcarles@vhio.net Current positions Head of the Genitourinary, CNS and Sarcoma Tumors Program. Associate Professor of Medicine at the Autonomous University of Barcelona and Coordinator of the optional subject of Medical OncologyANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcriptionCÉSAR SERRANO
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15;20 (22):5745-5755. George S, Barysauskas C, Serrano C, Oduyebo T,Rauh-Hain JA,
VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia.RODRIGO DIENSTMANN
2006-2009: Senior Clinical Research Fellow at National Cancer Institute, Brazil. 2010-2012: Fellowship at the Molecular Therapeutics Research Unit of VHIO, Spain. 2013: Fellowship at the Molecular Pathology Lab of the Massachusetts General Hospital, Boston, USA. 2013-2015: Research Scientist of the Computational Oncology Group atSage
ANA OAKNIN – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY ANA OAKNIN Current positions Principal Investigator, VHIO´s Gynecological Malignancies Group. Head of Gynecologic Tumors Unit, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Full-time Senior Medical Oncologist & Attending Physician, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Academic Qualifications Degree in Medicine and VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYABOUT VHIOPROGRAMS & GROUPSPRINCIPAL INVESTIGATORSCLINICAL TRIALSPROJECTS & INSTL PROGRAMS VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY Welcome to VHIO´s Intranet. Your very own personal dashboard provides you with confidential files including your salary details and your vacation records. You can also upload and organize your own documents, create groups with whom you wish to connect, browse up-to-the-minute VHIO news, and access a variety of organizational knowledge and EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCHEarly Clinical Drug Development Group. We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rational combinations of targeted therapies,biomarker-driven
ELENA GARRALDA
PubMed PMID: 30327308. Blanca Homet Moreno, Elena Garralda, Ricardo Hitt.Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas,Clinical & translational Oncology, Educational Series 2010: 12; 468-472. DOI 10.1007/s12094-010-0539-z. J. Sepulveda and E. Garralda.JOAN CARLES
JOAN CARLES jcarles@vhio.net Current positions Head of the Genitourinary, CNS and Sarcoma Tumors Program. Associate Professor of Medicine at the Autonomous University of Barcelona and Coordinator of the optional subject of Medical OncologyANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcriptionCÉSAR SERRANO
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15;20 (22):5745-5755. George S, Barysauskas C, Serrano C, Oduyebo T,Rauh-Hain JA,
VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia.RODRIGO DIENSTMANN
2006-2009: Senior Clinical Research Fellow at National Cancer Institute, Brazil. 2010-2012: Fellowship at the Molecular Therapeutics Research Unit of VHIO, Spain. 2013: Fellowship at the Molecular Pathology Lab of the Massachusetts General Hospital, Boston, USA. 2013-2015: Research Scientist of the Computational Oncology Group atSage
ANA OAKNIN – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY ANA OAKNIN Current positions Principal Investigator, VHIO´s Gynecological Malignancies Group. Head of Gynecologic Tumors Unit, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Full-time Senior Medical Oncologist & Attending Physician, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Academic Qualifications Degree in Medicine and VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: CONTACT – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY CELLEX CENTER C/ Natzaret, 115-117 08035 – BARCELONA – Spain Tel: +34 93 254 34 50 email: info@vhio.netJOAN CARLES
JOAN CARLES jcarles@vhio.net Current positions Head of the Genitourinary, CNS and Sarcoma Tumors Program. Associate Professor of Medicine at the Autonomous University of Barcelona and Coordinator of the optional subject of Medical Oncology VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia. NEWLY APPOINTED ESMO FACULTY: VHIO INVESTIGATORS JOIN In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core priorities and objectives set out in its Vision 2020, ESMO has finalized its 2021 composition of expert committees and working groups, including newly appointed faculty members across various tumor types.. ESMO’s serving officers, including those who have just RAQUEL PÉREZ-LÓPEZ 2014 Prostate Cancer UK Movember Translations Research Grant PG14-016-TR2 (co- investigator; PI Dr. Koh). 2011 European School Of Radiologist (ESOR) Scholarship Grant. Personalized REsponse Imaging biomarker for Cancer immunotherapy. CRIS Research Talent Program from the CRIS Cancer Foundation. PI: Raquel Perez-Lopez.RODRIGO DIENSTMANN
2006-2009: Senior Clinical Research Fellow at National Cancer Institute, Brazil. 2010-2012: Fellowship at the Molecular Therapeutics Research Unit of VHIO, Spain. 2013: Fellowship at the Molecular Pathology Lab of the Massachusetts General Hospital, Boston, USA. 2013-2015: Research Scientist of the Computational Oncology Group atSage
JUDITH BALMAÑA
Most relevant scientific publications. Montalban G, Bonache S, Moles-Fernández A, Gisbert-Beamud A, Tenés A, Bach V, Carrasco E, López-Fernández A, Stjepanovic N, Balmaña J, Diez O, Gutiérrez-Enríquez S. Screening of BRCA1/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast/ovarian cancer.PAOLO G. NUCIFORO
Academic Qualifications. 1997 Degree in Medicine and Surgery from the University of Catania (Italy) 2002 Board certification in Pathology from the University of Milan (Italy) 2003 2005 Research fellow at Firc Institute of Molecular Oncology, Milan. 2005-2007 Molecular Pathology Unit Coordinator at Firc Institute of Molecular Oncology, Milan.ONCOTRIALSTRACK
OncoTrialsTrack. Information displayed in OncoTrialsTrack is constantly updated but specific clinical trial recruitment plans may change on a daily basis. Therefore, clinical trial availability must be confirmed with principal investigators of the site. VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYABOUT VHIOPROGRAMS & GROUPSPRINCIPAL INVESTIGATORSCLINICAL TRIALSPROJECTS & INSTL PROGRAMS VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY Welcome to VHIO´s Intranet. Your very own personal dashboard provides you with confidential files including your salary details and your vacation records. You can also upload and organize your own documents, create groups with whom you wish to connect, browse up-to-the-minute VHIO news, and access a variety of organizational knowledge and EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCHEarly Clinical Drug Development Group. We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rational combinations of targeted therapies,biomarker-driven
ELENA GARRALDA
PubMed PMID: 30327308. Blanca Homet Moreno, Elena Garralda, Ricardo Hitt.Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas,Clinical & translational Oncology, Educational Series 2010: 12; 468-472. DOI 10.1007/s12094-010-0539-z. J. Sepulveda and E. Garralda.JOAN CARLES
JOAN CARLES jcarles@vhio.net Current positions Head of the Genitourinary, CNS and Sarcoma Tumors Program. Associate Professor of Medicine at the Autonomous University of Barcelona and Coordinator of the optional subject of Medical OncologyANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcriptionCÉSAR SERRANO
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15;20 (22):5745-5755. George S, Barysauskas C, Serrano C, Oduyebo T,Rauh-Hain JA,
VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia.RODRIGO DIENSTMANN
2006-2009: Senior Clinical Research Fellow at National Cancer Institute, Brazil. 2010-2012: Fellowship at the Molecular Therapeutics Research Unit of VHIO, Spain. 2013: Fellowship at the Molecular Pathology Lab of the Massachusetts General Hospital, Boston, USA. 2013-2015: Research Scientist of the Computational Oncology Group atSage
ANA OAKNIN – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY ANA OAKNIN Current positions Principal Investigator, VHIO´s Gynecological Malignancies Group. Head of Gynecologic Tumors Unit, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Full-time Senior Medical Oncologist & Attending Physician, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Academic Qualifications Degree in Medicine and VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYABOUT VHIOPROGRAMS & GROUPSPRINCIPAL INVESTIGATORSCLINICAL TRIALSPROJECTS & INSTL PROGRAMS VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: VHIO - VALL D'HEBRON INSTITUTE OF ONCOLOGY Welcome to VHIO´s Intranet. Your very own personal dashboard provides you with confidential files including your salary details and your vacation records. You can also upload and organize your own documents, create groups with whom you wish to connect, browse up-to-the-minute VHIO news, and access a variety of organizational knowledge and EARLY CLINICAL DRUG DEVELOPMENT GROUP CLINICAL RESEARCHEarly Clinical Drug Development Group. We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and immuno-oncology. These include first-in-human studies of targeted therapies, rational combinations of targeted therapies,biomarker-driven
ELENA GARRALDA
PubMed PMID: 30327308. Blanca Homet Moreno, Elena Garralda, Ricardo Hitt.Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas,Clinical & translational Oncology, Educational Series 2010: 12; 468-472. DOI 10.1007/s12094-010-0539-z. J. Sepulveda and E. Garralda.JOAN CARLES
JOAN CARLES jcarles@vhio.net Current positions Head of the Genitourinary, CNS and Sarcoma Tumors Program. Associate Professor of Medicine at the Autonomous University of Barcelona and Coordinator of the optional subject of Medical OncologyANA VIVANCOS
ANA VIVANCOS avivancos@vhio.net Current positions Principal Investigator, Cancer Genomics Group Reviewer for: Clinical Cancer Research, Nature, and Oncogene. Academic Qualifications PhD, Biochemistry and Molecular Biology, Universitat Pompeu Fabra, 2006. Dissertation: Role of the peroxiredoxin Tpx1 and the transcriptionCÉSAR SERRANO
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res. 2014 Nov 15;20 (22):5745-5755. George S, Barysauskas C, Serrano C, Oduyebo T,Rauh-Hain JA,
VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia.RODRIGO DIENSTMANN
2006-2009: Senior Clinical Research Fellow at National Cancer Institute, Brazil. 2010-2012: Fellowship at the Molecular Therapeutics Research Unit of VHIO, Spain. 2013: Fellowship at the Molecular Pathology Lab of the Massachusetts General Hospital, Boston, USA. 2013-2015: Research Scientist of the Computational Oncology Group atSage
ANA OAKNIN – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY ANA OAKNIN Current positions Principal Investigator, VHIO´s Gynecological Malignancies Group. Head of Gynecologic Tumors Unit, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Full-time Senior Medical Oncologist & Attending Physician, Medical Oncology Department, the Vall d´Hebron University Hospital (HUVH). Academic Qualifications Degree in Medicine and VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer: CONTACT – VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGY CELLEX CENTER C/ Natzaret, 115-117 08035 – BARCELONA – Spain Tel: +34 93 254 34 50 email: info@vhio.netJOAN CARLES
JOAN CARLES jcarles@vhio.net Current positions Head of the Genitourinary, CNS and Sarcoma Tumors Program. Associate Professor of Medicine at the Autonomous University of Barcelona and Coordinator of the optional subject of Medical Oncology VHIO – VALL D'HEBRON INSTITUTE OF ONCOLOGYTRANSLATE THIS PAGE VHIO – Vall d'Hebron Institute of Oncology. Comunicado del Patronato del VHIO. en relación al fallecimiento del Dr. José Baselga. Omomyc, un fármaco desarrollado. en el VHIO, llega al ensayo clínico. Vall d’Hebron desarrolla un método poco invasivo. que permite predecir cómo responderán. las metástasis cerebrales a la inmunoterapia. NEWLY APPOINTED ESMO FACULTY: VHIO INVESTIGATORS JOIN In parallel with the European Society for Medical Oncology’s (ESMO) publication of its 2025 Vision, which builds on the core priorities and objectives set out in its Vision 2020, ESMO has finalized its 2021 composition of expert committees and working groups, including newly appointed faculty members across various tumor types.. ESMO’s serving officers, including those who have just RAQUEL PÉREZ-LÓPEZ 2014 Prostate Cancer UK Movember Translations Research Grant PG14-016-TR2 (co- investigator; PI Dr. Koh). 2011 European School Of Radiologist (ESOR) Scholarship Grant. Personalized REsponse Imaging biomarker for Cancer immunotherapy. CRIS Research Talent Program from the CRIS Cancer Foundation. PI: Raquel Perez-Lopez.RODRIGO DIENSTMANN
2006-2009: Senior Clinical Research Fellow at National Cancer Institute, Brazil. 2010-2012: Fellowship at the Molecular Therapeutics Research Unit of VHIO, Spain. 2013: Fellowship at the Molecular Pathology Lab of the Massachusetts General Hospital, Boston, USA. 2013-2015: Research Scientist of the Computational Oncology Group atSage
JUDITH BALMAÑA
Most relevant scientific publications. Montalban G, Bonache S, Moles-Fernández A, Gisbert-Beamud A, Tenés A, Bach V, Carrasco E, López-Fernández A, Stjepanovic N, Balmaña J, Diez O, Gutiérrez-Enríquez S. Screening of BRCA1/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast/ovarian cancer.PAOLO G. NUCIFORO
Academic Qualifications. 1997 Degree in Medicine and Surgery from the University of Catania (Italy) 2002 Board certification in Pathology from the University of Milan (Italy) 2003 2005 Research fellow at Firc Institute of Molecular Oncology, Milan. 2005-2007 Molecular Pathology Unit Coordinator at Firc Institute of Molecular Oncology, Milan.ONCOTRIALSTRACK
OncoTrialsTrack. Information displayed in OncoTrialsTrack is constantly updated but specific clinical trial recruitment plans may change on a daily basis. Therefore, clinical trial availability must be confirmed with principal investigators of the site.Accept
This website uses cookies to ensure you get the best experience on ourwebsite More info
Cookie Consent plugin for the EU cookie law Toggle SlidingBar Area* INTRANET
* WEBMAIL
* Language:
* Catal
* Castellano
* English
* INTRANET
* WEBMAIL
* Language:
* Catal
* Castellano
* English
TRANSLATION TOWARD
PRECISION ONCOLOGY
* About Vhio
* WHO WE ARE
* ORGANIZATION
* TRUSTEES
* SCIENTIFIC REPORTS* WORK WITH US
* QUALITY ASSURANCE
* HRS4R
* VALL D’HEBRON UNIVERSITY HOSPITAL* CORPORATE VIDEO
* Programs & Groups
* PRECLINICAL & TRANSLATIONAL RESEARCH* CLINICAL RESEARCH
* CORE TECHNOLOGIES
* Principal Investigators* MARÍA ABAD
* JOAQUIN ARRIBAS
* JUDITH BALMAÑA
* FRANCESC BOSCH
* FRANCESC CANALS
* JOAN CARLES
* RODRIGO DIENSTMANN* ENRIQUETA FELIP
* ELENA GARRALDA
* JORDI GIRALT
* ALENA GROS
* TERESA MACARULLA
* JOAQUIN MATEO
* PAOLO G. NUCIFORO
* ANA OAKNIN
* HÉCTOR G. PALMER
* SANDRA PEIRÓ
* RAQUEL PEREZ-LOPEZ* CRISTINA SAURA
* JOAN SEOANE
* VIOLETA SERRA
* CÉSAR SERRANO
* LAURA SOUCEK
* JOSEP TABERNERO
* JOSEP VILLANUEVA
* ANA VIVANCOS
* Clinical trials
* CLINICAL TRIALS AT VHIO * CLINICAL TRIALS OFFICE * RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER “LA CAIXA” * CURRENTLY OPEN TRIALS * CLINICAL RESEARCH ONCOLOGY NURSES * CLINICAL RESEARCH ONCOLOGY PHARMACY UNIT * PROJECTS & INSTL PROGRAMS * SCIENTIFIC COORDINATION AREA* CURRENT PROJECTS
* FERO FOUNDATION’s ADVANCED MOLECULAR DIAGNOSTICS PROGRAM * BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI) * “LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM * FUNDING, CONSORTIA & ACCREDITATION* CONTACT US
* News
* Events
* VHIO – ”la Caixa” SCIENTIFIC SEMINARS SERIES * Symposia & Conferences * VHIO _MEET THE EDITORS_ * Workshops & Courses * BENCHSTORMING SEMINARS* Media
* VHIO IN THE MEDIA
* SCIENTIFIC REPORTS* About Vhio
* WHO WE ARE
* ORGANIZATION
* TRUSTEES
* SCIENTIFIC REPORTS* WORK WITH US
* QUALITY ASSURANCE
* HRS4R
* VALL D’HEBRON UNIVERSITY HOSPITAL* CORPORATE VIDEO
* Programs & Groups
* PRECLINICAL & TRANSLATIONAL RESEARCH* CLINICAL RESEARCH
* CORE TECHNOLOGIES
* Principal Investigators* MARÍA ABAD
* JOAQUIN ARRIBAS
* JUDITH BALMAÑA
* FRANCESC BOSCH
* FRANCESC CANALS
* JOAN CARLES
* RODRIGO DIENSTMANN* ENRIQUETA FELIP
* ELENA GARRALDA
* JORDI GIRALT
* ALENA GROS
* TERESA MACARULLA
* JOAQUIN MATEO
* PAOLO G. NUCIFORO
* ANA OAKNIN
* HÉCTOR G. PALMER
* SANDRA PEIRÓ
* RAQUEL PEREZ-LOPEZ* CRISTINA SAURA
* JOAN SEOANE
* VIOLETA SERRA
* CÉSAR SERRANO
* LAURA SOUCEK
* JOSEP TABERNERO
* JOSEP VILLANUEVA
* ANA VIVANCOS
* Clinical trials
* CLINICAL TRIALS AT VHIO * CLINICAL TRIALS OFFICE * RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER “LA CAIXA” * CURRENTLY OPEN TRIALS * CLINICAL RESEARCH ONCOLOGY NURSES * CLINICAL RESEARCH ONCOLOGY PHARMACY UNIT * PROJECTS & INSTL PROGRAMS * SCIENTIFIC COORDINATION AREA* CURRENT PROJECTS
* FERO FOUNDATION’s ADVANCED MOLECULAR DIAGNOSTICS PROGRAM * BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI) * “LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM * FUNDING, CONSORTIA & ACCREDITATION* CONTACT US
* News
* Events
* VHIO – ”la Caixa” SCIENTIFIC SEMINARS SERIES * Symposia & Conferences * VHIO _MEET THE EDITORS_ * Workshops & Courses * BENCHSTORMING SEMINARS* Media
* VHIO IN THE MEDIA
* SCIENTIFIC REPORTS*
Integrating Genomics and Transcriptomics to reshapePrecision Oncology:
a
Win
ning strategy
*
VHIO-“la Caixa”
Advanced Oncology Research Program: accelerating progress and pushing boundaries in precision oncology*
World Cancer Day 2020: International survey reveals unacceptable cancer awareness divide*
PI3K blockade in HR-positive breast cancer: the ringing in of a more precise and potent clinical futureABOUT VHIO
VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer:DISCOVER MORE
PROGRAMS & GROUPS
Scientific activity at VHIO is structured across for major programs: Preclinical, Translational, Clinical Research, and Core Technologies. Each incorporates research teams of excellence dedicated to harnessing and rapidly translating discoveries into tangible benefits forpatients.
MEET VHIO´S TEAMS
NEWS
*
*
*
VHIO-“LA CAIXA” ADVANCED ONCOLOGY RESEARCH PROGRAM: ACCELERATING PROGRESS AND PUSHING BOUNDARIES IN PRECISION ONCOLOGY 14/02/2020|Comments Off on VHIO-“la Caixa” Advanced Oncology Research Program: accelerating progress and pushing boundaries inprecision oncology
*
*
*
ADVANCES AND NEW HORIZONS IN THE DIAGNOSIS AND TREATMENT OF COLORECTALCANCER
10/02/2020|Comments Off on Advances and new horizons in the diagnosis and treatment of colorectal cancer*
*
*
WORLD CANCER DAY 2020: INTERNATIONAL SURVEY REVEALS UNACCEPTABLE CANCER AWARENESS DIVIDE 04/02/2020|Comments Off on World Cancer Day 2020: International survey reveals unacceptable cancer awareness divide*
*
*
WORLD CANCER DAY’S CALL TO ACT FOR A CANCER-FREE WORLD: WHAT WILL YOU PLEDGE TO HELP REDUCE THE GLOBAL BURDEN OF DISEASE? 03/02/2020|Comments Off on World Cancer Day’s call to act for a cancer-free world: what will you pledge to help reduce the globalburden of disease?
*
*
*
MARKING JANUARY’S CERVICAL CANCER AWARENESS MONTH: ANA OAKNIN ON ACTIONS AND ADVANCES AGAINST THIS DISEASE 21/01/2020|Comments Off on Marking January’s Cervical Cancer Awareness Month: Ana Oaknin on actions and advances against thisdisease
*
*
*
PI3K BLOCKADE IN HR-POSITIVE BREAST CANCER: THE RINGING IN OF A MORE PRECISE AND POTENT CLINICAL FUTURE 09/01/2020|Comments Off on PI3K blockade in HR-positive breast cancer: the ringing in of a more precise and potent clinical futureSEE ALL NEWS
FOLLOW US:
DIRECTION &
PRINCIPAL INVESTIGATORS*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Research at VHIO is led by our Director, Josep Tabernero, and supported by a consultative body, VHIO’s Scientific Committee. A total of 26 renowned Principal Investigators manage and run VHIO’s major research themes and programs.BROWSE OUR PIS
SCIENTIFIC
REPORT
2018
LAUNCH
CLINICAL TRIALS
Driving drug development & targeted therapies against cancer, VHIO has become a leading reference in drug discovery from concept to clinic: CLINICAL TRIALS OFFICE RESEARCH UNIT FOR MOLECULAR THERAPY OF CANCER – “LA CAIXA” CURRENTLY OPEN TRIALS*
*
*
*
*
*
PROJECTS & INSTITUTIONAL PROGRAMS Research at VHIO is made possible through the support received from private institutions, funding entities, companies and individuals, as well as International and National Competitive Grants. Find out more about our supporters, current projects and VHIO´s ScientificCoordination Area:
CURRENT PROJECTS
FERO FOUNDATION’S ADVANCED MOLECULAR DIAGNOSTICS PROGRAM BBVA FOUNDATION’S IMMUNOTHERAPY & IMMUNOLOGY PROGRAM (CAIMI) “LA CAIXA” INTL RESEARCH & EDUCATION PROGRAM SCIENTIFIC COORDINATION*
*
EVENTS
VHIO organizes symposia of excellence and ad-hoc courses & workshops through which it shares its expertise and promotes debate and exchange of the highest degree: VHIO – ”LA CAIXA” SCIENTIFIC SEMINARS SERIES INTERNATIONAL SYMPOSIAWORKSHOPS & COURSES
BENCHSTORMING SEMINARS*
*
*
*
CELLEX CENTER
C/ Natzaret, 115-117 08035 - BARCELONA - Spain Tel: +34 93 254 34 50 email: info@vhio.net* CONTACT
* RSS
* TRANSPARENCY PORTAL* LEGAL ADVICE
Vall d'Hebron Institute of Oncology (VHIO)Go to Top
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0